Texas Retina’s Diana M. Laura, MD, participated in a debate at the 13th Annual Vit-Buckle Society Meetingheld recently in Austin, Texas, where she discussed the role of complement inhibitors for the treatment of dry age-related macular degeneration (AMD).
Complement inhibitors are drugs that block the activity of the complement system, helping to prevent overactivation of the immune system and reduce inflammation. Two FDA-approved complement inhibitors — pegcetacoplan (Syfovre, a C3 inhibitor) and avacincaptad pegol (Izervay, a C5 inhibitor) — have shown promise in slowing the progression of geographic atrophy (GA) secondary to dry AMD. Texas Retina was actively involved in the clinical trials that led to the approvals of Syfovre (OAKS and DERBY) and Izervay (GATHER1 and GATHER2).
About The Vit-Buckle Society
Founded in 2005 as a non-profit, voluntary organization dedicated to enhancing retina education, The Vit-Buckle Society provides an open forum that mentors developing vitreoretinal surgeons, nurtures innovative surgical technologies and therapeutic approaches for retinal diseases, and fosters best practices.
About Diana M. Laura, MD
Dr. Laura joined Texas Retina in September 2022, and cares for patients in our Dallas Main, Rockwall and Wichita Falls offices. She completed her vitreoretinal surgery fellowship and ophthalmology residency at Bascom Palmer Eye Institute at the University of Miami, one of the top-rated eye hospitals in the country. While there, she served as Chief Resident and as Co-Director of Ocular Trauma.
At Texas Retina, Dr. Laura provides care for a full range of vitreoretinal conditions, including AMD, retinal tears and detachment, diabetic retinopathy, ocular trauma, retinopathy of prematurity and other pediatric retinal diseases. She is passionate about research to discover new and better treatments to restore and maintain vision.
Click here to learn more about Dr. Laura.